Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche and Blueprint pursue immunotherapy

by Lisa M. Jarvis
March 21, 2016 | A version of this story appeared in Volume 94, Issue 12

Roche will pay Blueprint Medicines $45 million up front as part of a broad pact to develop small-molecule cancer immunotherapies. Roche has the option to license up to five small molecules targeting immunokinases, proteins that play a role in regulating immune cells’ response. Blueprint is tasked with early development of the drug candidates, and Roche can buy into each program after Phase I data are available. Blueprint could secure close to $1 billion more in option and milestone fees if Roche licenses all five programs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.